Lytix Biopharma ASA

As of June 30, 2026, Lytix Biopharma ASA carries a market capitalization of 707.48M, placing it among publicly traded companies globally. Its enterprise value stands at 617.86M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Lytix Biopharma ASA has 76.90M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Lytix Biopharma ASA maintains a current ratio of 7.60, meaning it holds 7.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.04, indicating elevated leverage, while an interest coverage ratio of -1,195.77 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Lytix Biopharma ASA posted a negative return on equity (ROE) of -107.13, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -89.91, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 6.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Lytix Biopharma ASA's stock has gained approximately 8.08% over the past 52 weeks. The 50-day moving average sits at 8.17, while the 200-day moving average is 9.29.

Over the twelve months ended June 30, 2026, Lytix Biopharma ASA generated - - in revenue and converted that into -94.61M in net income, yielding earnings per share of -1.30. EBITDA reached -98.05M, while operating income came in at -99.05M.

As of June 30, 2026, Lytix Biopharma ASA holds 91.39M in cash and equivalents against 1.77M in total debt, resulting in a net debt position of -29.00M. Total book value stands at 86.62M, with working capital of 85.69M providing operational flexibility.

Lytix Biopharma ASA produced -87.00M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -87.00M - equivalent to -1.20 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -13.00: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.71, meaning Lytix Biopharma ASA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Lytix Biopharma ASA's most recent stock split took place on January 9, 2026 with a 211:212 split ratio.